1. Introduction {#sec1-ijms-18-02479}
===============

Estrogen is responsible for breast cancer growth. The target genes of an estrogen receptor are in control of cancer cell development in estrogen-dependent breast tumors. Binding of estrogen receptor to estrogen triggers transcription of its target genes \[[@B1-ijms-18-02479]\]. Aromatase is the rate-limiting enzyme in estrogen biosynthesis \[[@B1-ijms-18-02479]\]. This enzyme converts androgens (testosterone and androtestosterone) into estrogens (estradiol and estrone, respectively) \[[@B2-ijms-18-02479]\]. Aromatase inhibitors (AIs) are adjuvant in hormone treatments commonly prescribed for breast cancers that are hormone receptor-positive in the early stage \[[@B3-ijms-18-02479]\]. However, the currently used AIs have several side effects of menopausal symptoms such as hot flashes, vaginal dryness, sexual dysfunction, musculoskeletal symptoms, osteoporosis, bone fracture, fatigue, mood disturbance, nausea, and vomiting \[[@B3-ijms-18-02479]\]. Therefore, natural compounds obtained from safe food resources might be useful in the search for promoter-specific AIs with few side effects \[[@B4-ijms-18-02479]\].

*Pleurotus eryngii* (Japanese name: eringi, English name: oyster mushroom or king trumpet) is an edible mushroom. *P. eryngii* is native to North Africa, Asia, and Europe \[[@B5-ijms-18-02479]\], and also grown commercially in Japan, China, and the US \[[@B6-ijms-18-02479]\]. Previous studies demonstrated the inhibitory effects on human neutrophil elastase (HNE) \[[@B7-ijms-18-02479]\], antioxidant and antimutagenic activities \[[@B8-ijms-18-02479]\], and inhibitory effects on allergic mediators \[[@B9-ijms-18-02479]\] of *P. eryngii* extracts. *P. eryngii* contains amino acids, vitamins, and dietary fiber \[[@B10-ijms-18-02479]\]. It also includes polysaccharides \[[@B11-ijms-18-02479],[@B12-ijms-18-02479]\], pleurone \[[@B7-ijms-18-02479]\], ergostane-type sterols \[[@B13-ijms-18-02479]\], and eryngiolide A \[[@B14-ijms-18-02479]\]. These chemical constituents exhibit biological activities such as the antioxidant \[[@B11-ijms-18-02479]\] and antitumor activities \[[@B12-ijms-18-02479]\] of a polysaccharide, HNE-inhibitory effects of pleurone \[[@B7-ijms-18-02479]\], and cytotoxicity against human cancer cell lines of eryngiolide A \[[@B14-ijms-18-02479]\]. We recently reported eringiacetal A, which is an ergostane-type sterol with a cage-shaped structure \[[@B15-ijms-18-02479]\], and a 9,11-*seco*-ergostane and five ergostane-type sterols \[[@B16-ijms-18-02479]\] from the fruiting bodies of *P. eryngii*. In a continuing study, we isolated 10 ergostane-type sterols, and elucidated the structures of two new compounds; (22*E*)-5α,6α-epoxyergosta-8,14,22-triene-3β,7β-diol (**1**), and 5α,6α-epoxyergost-8(14)-ene-3β,7α-diol (**2**). In addition, the isolated constituents were evaluated for inhibitory activities on aromatase.

2. Results {#sec2-ijms-18-02479}
==========

2.1. Isolation and Structure Elucidation {#sec2dot1-ijms-18-02479}
----------------------------------------

(22*E*)-Ergosta-7,22-dien-3β-ol (**3**) \[[@B17-ijms-18-02479]\], (22*E*)-ergosta-5,7,22-trien-3β-ol (**4**) \[[@B18-ijms-18-02479]\], (22*E*)-19-norergosta-5,7,9,22-tetraen-3β-ol (**5**) \[[@B19-ijms-18-02479]\], ergosterol peroxide (**9**) \[[@B18-ijms-18-02479]\], and 9,11-dehydroergosterol peroxide (**10**) \[[@B20-ijms-18-02479]\] were isolated from sample 1, and Compounds **1**, **2**, (22*E*)-6β-methoxyergosta-7,22-diene-3β,5α-diol (**6**) \[[@B21-ijms-18-02479]\], (22*E*)-3β,5α,9α-trihydroxyergosta-7,22-dien-6-one (**7**) \[[@B21-ijms-18-02479]\], and (22*E*)-3β,5α-dihydroxyergosta-7,22-dien-6-one (**8**) \[[@B22-ijms-18-02479]\] were obtained from sample 2 ([Figure 1](#ijms-18-02479-f001){ref-type="fig"}). Of these, **1** and **2** were new compounds.

Compound **1** was isolated as an amorphous solid, with a molecular formula of C~28~H~42~O~3~ by HREIMS. The infrared (IR) spectrum indicated the presence of hydroxy groups (*ν*~max~ 3451 cm^−1^), and the UV spectrum suggested the presence of a conjugated diene (*λ*~max~ 242.0 nm). The ^1^H and ^13^C NMR spectra (*δ*~H~ and *δ*~C~ in ppm) in CDCl~3~ displayed signals for two tertiary methyls (*δ*~H~ 0.82 (singlet (s)), 1.30 (s)), four secondary methyls (*δ*~H~ 0.83 (doublet (d)), 0.85 (d), 0.93 (d), 1.04 (d)), three oxymethines (*δ*~H~ 3.24 (d), 3.96 (triplet of triplets (tt)), 4.85 (broad singlet (br s)); *δ*~C~ 59.5 (d), 63.8 (d), 68.4 (d)), an sp^3^ oxygenated quaternary carbon (*δ*~C~ 63.3 (s)), a tetrasubstituted olefin (*δ*~C~ 122.2 (s), 138.8 (s)), a trisubstituted olefin (*δ*~H~ 5.55 (br s); *δ*~C~ 118.7 (d), 147.7 (s)), and a disubstutited olefin (*δ*~H~ 5.20 (doublet of doublets (dd)), 5.28 (dd); *δ*~C~ 132.4 (d), 135.1 (d)) ([Table 1](#ijms-18-02479-t001){ref-type="table"}, [Figures S1--S4](#app1-ijms-18-02479){ref-type="app"}). In the HMBC spectrum, the correlations were observed as follows; Me-19 (*δ*~H~ 0.82 (s))/C-5 (*δ*~C~ 63.3 (s)), C-9 (*δ*~C~ 138.8 (s)); H-7 (*δ*~H~ 4.85 (br s))/C-5 (*δ*~C~ 63.3 (s)), C-9 (*δ*~C~ 138.8 (s)), C-14 (*δ*~C~ 147.7 (s)); H-6 (*δ*~H~ 3.24 (d))/C-7 (*δ*~C~ 63.8 (d)), C-8 (*δ*~C~ 122.2 (s)); Me-18 (*δ*~H~ 0.82 (s))/C-14 (*δ*~C~ 147.7 (s)); Me-28 (*δ*~H~ 0.93 (d))/C-23 and C-25 ([Figure 2](#ijms-18-02479-f002){ref-type="fig"}A and [Figure S5](#app1-ijms-18-02479){ref-type="app"}). The correlations between H~2~-1--H~2~-2--H-3 (*δ*~H~ 3.96 (tt))--H~2~-4; H-6 (*δ*~H~ 3.24 (d))--H-7 (*δ*~H~ 4.85 (br s)); H-15 (*δ*~H~ 5.55 (br s))--H~2~-16--H-17--H-20--Me-21; H-20--H-22 (*δ*~H~ 5.20 (dd))--H-23 (*δ*~H~ 5.28 (dd))--H-24--Me-28 (*δ*~H~ 0.93 (d)); Me-26 (*δ*~H~ 0.85 (d))--H-25--Me-27 (*δ*~H~ 0.83 (d)) were observed in the ^1^H-^1^H COSY spectrum ([Figure 2](#ijms-18-02479-f002){ref-type="fig"}A and [Figure S6](#app1-ijms-18-02479){ref-type="app"}). From the above, the planar structure was determined as shown in [Figure 2](#ijms-18-02479-f002){ref-type="fig"}A. The configuration of the hydroxy groups at the C-3 position was determined as β-orientation because of the coupling constant (*J*) (*δ*~H~ 3.96 (tt, 11.5, 5.4 Hz)). The NOE correlation of Me-19/H-6β (equatrial) suggested that the epoxy group at C-5,6 was α-oriented, and that of H-7α/H-15 suggested that 7-OH was β-oriented ([Figure 2](#ijms-18-02479-f002){ref-type="fig"}B and [Figure S7](#app1-ijms-18-02479){ref-type="app"}). The geometry of the double bond at C-22 was determined as *E* from the coupling constants of H-22 (*δ*~H~ 5.20 (dd, *J* = 15.2, 7.6 Hz)) and H-23 (*δ*~H~ 5.28 (dd, *J* = 15.2, 7.9 Hz)). Comparison of ^13^C NMR chemical shifts at C-24 (*δ*~C~ 42.8) and 28 (*δ*~C~ 17.6) with those of 24*R* (*δ*~C~ 42.9 (C-24) and 17.7 (C-28)) and 24*S* (*δ*~C~ 43.2 (C-24) and 18.1 (C-28)) methylcholestane-type sterols \[[@B23-ijms-18-02479],[@B24-ijms-18-02479]\] established the stereochemistry of C-24 as *R*. Therefore compound **1** was determined as (22*E*)-5α,6α-epoxyergosta-8,14,22-triene-3β,7β-diol ([Figure 1](#ijms-18-02479-f001){ref-type="fig"}, [Table S1](#app1-ijms-18-02479){ref-type="app"}). Compound **1** was similar to (22*E*)-5α,6α-epoxy-ergosta-8,14,22-triene-7β,7α-diol \[[@B25-ijms-18-02479]\], except for the absence of a 7α-hydroxy group and the presence of a 7β-hydroxy group. There are differences in *δ*~H~ value measured with C~6~D~6~ such as H-7 (7α-hydroxy-type: *δ*~H~ 4.34 (1H, dd, *J* = 11.2, 2.6 Hz) \[[@B25-ijms-18-02479]\] vs. 7β-hydroxy-type (**1**): *δ*~H~ 4.74 (br s)), and H-15 (7α-hydroxy-type: *δ*~H~ 6.50 (1H, dd, *J* = 3.3, 1.8 Hz) \[[@B25-ijms-18-02479]\] vs. 7β-hydroxy-type (**1**): *δ*~H~ 5.33 (br s)).

Compound **2** was isolated as an amorphous solid, with a molecular formula of C~28~H~46~O~3~. The IR spectrum suggested the presence of hydroxy groups (3387 cm^−1^). The ^1^H, ^13^C NMR and HSQC spectra indicated the presence of two tertiary methyls (*δ*~H~ 0.85 (s), 0.87 (s)), four secondary methyls (*δ*~H~ 0.77 (d), 0.78 (d), 0.85 (d), 0.93 (d)), two oxymethines (*δ*~H~ 3.92 (tt), 4.43 (dd); *δ*~C~ 65.1 (d), 68.7 (d)), a trisubstituted epoxy (*δ*~H~ 3.15 (d); *δ*~C~ 61.3 (d), 67.8 (s)), and a tetrasubstituted olefin (*δ*~C~ 125.1 (s), 152.7 (s)) ([Table 1](#ijms-18-02479-t001){ref-type="table"}, [Figures S8--S11](#app1-ijms-18-02479){ref-type="app"}). Based on the correlations at Me-18/C-14 (*δ*~C~ 152.7 (s)), Me-19/C-5 (*δ*~C~ 67.8 (s)), and H-15/C-8 (*δ*~C~ 125.1 (s)) and C-14 (*δ*~C~ 152.7 (s)) in the HMBC spectrum, and H~2~-1--H~2~-2--H-3 (*δ*~H~ 3.92 (tt))--H~2~-4; H-6 (*δ*~H~ 3.15 (d))--H-7 (*δ*~H~ 4.43 (dd)) in the ^1^H-^1^H COSY spectrum ([Figure 3](#ijms-18-02479-f003){ref-type="fig"}A, [Figures S12 and S13](#app1-ijms-18-02479){ref-type="app"}), oxymethines were at C-3 and C-7 positions, a trisubstituted epoxy group at the C-5, 6 positions, and a tetrasubstituted olefin at the C-8, 14 positions ([Figure 3](#ijms-18-02479-f003){ref-type="fig"}A). The NOE correlation between H-7 and Me-19 demonstrated the configuration of the hydroxy group at the C-7 position as α-orientation ([Figure 3](#ijms-18-02479-f003){ref-type="fig"}B and [Figure S14](#app1-ijms-18-02479){ref-type="app"}). The NOE correlation between H-4β and Me-19 suggested the orientation of the epoxy group at C-5, 6 was α ([Figure 3](#ijms-18-02479-f003){ref-type="fig"}B and [Figure S14](#app1-ijms-18-02479){ref-type="app"}). The stereochemistry of C-24 was established as *S* by comparison of the ^1^H NMR chemical shift at Me-28 (*δ*~H~ 0.77) with those of 24*R* (*δ*~H~ 0.802) and 24*S* (*δ*~H~ 0.781) ergostane-type sterols \[[@B26-ijms-18-02479],[@B27-ijms-18-02479]\]. Therefore, the structure of **2** was established as 5α,6α-epoxyergosta-8(14)-ene-3β,7α-diol ([Figure 1](#ijms-18-02479-f001){ref-type="fig"}, [Table S2](#app1-ijms-18-02479){ref-type="app"}).

2.2. Evaluation for Aromatase Inhibitory Effects {#sec2dot2-ijms-18-02479}
------------------------------------------------

Compounds **1**--**10** and aminoglutethimide, a positive control, were evaluated for their aromatase inhibitory activities. Compounds **4** and **6** exhibited comparable inhibitory activities (IC~50~ **4**: 8.1 µM; **6**: 2.8 µM) to aminoglutethimide (IC~50~ 2.0 µM) ([Figure 4](#ijms-18-02479-f004){ref-type="fig"}A). Compounds **1**, **3**, **5**, and **10** showed moderate activities (IC~50~ **1**: 17.3 µM; **3**: 66.1 µM; **5**: 33.8 µM; **10**: 32.6 µM) ([Figure 4](#ijms-18-02479-f004){ref-type="fig"}B). Compounds **2**, **7**, **8**, and **9** weakly inhibited aromatase ([Figure 4](#ijms-18-02479-f004){ref-type="fig"}B). Above results suggested that compounds **4** and **6** can be regarded as potential anti-breast cancer agents targeting aromatase. Based on the results in the figures, the following structure-activity relationship of the compounds can be concluded: (i) The double-bond at C-5, 6 intensifies the aromatase inhibitory activity in ergost-7-ene compounds (**3** (IC~50~ 66.1 µM) vs. **4** (IC~50~ 8.1 µM)); (ii) 9(11)-double-bond enhances the inhibitory activity in 5α,8α-epidioxyergost-6-ene compounds (**9** (IC~50~ \> 100 µM) vs. **10** (IC~50~ 32.6 µM)); (iii) 7-ene-6-one compounds did not show this activity (**7** and **8** (IC~50~ \> 100 µM)).

3. Experimental Section {#sec3-ijms-18-02479}
=======================

3.1. General Methods {#sec3dot1-ijms-18-02479}
--------------------

Dibenzylfluorescein (DBF) and Human CYP19 + P450 Reductase SUPERSOMES (human recombinant aromatase) were obtained from BD Biosciences (Heidelberg, Germany). The physical data were obtained by the following instruments: a Yanagimoto micro-melting point apparatus for melting points (uncorrected); a JASCO DIP-1000 digital polarimeter for Optical rotations; a Perkin-Elmer 1720X FTIR spectrophotometer for IR spectra; an Agilent-NMR-vnmrs600 for the ^1^H and ^13^C NMR spectra (^1^H: 600 MHz; ^13^C: 150 MHz) in CDCl~3~ with tetramethylsilane as the internal standard; a Hitachi M-4000H double-focusing mass spectrometer for EIMS (70 eV). Column chromatography was carried out by Silica gel (70--230 mesh, Merck, Darmstadt, Germany) and silica gel 60 (230--400 mesh, Nacalai Tesque, Inc*.,* Kyoto, Japan). HPLC was performed by the following systems; system I: *Cosmosil 5SL-II column* (25 cm × 20 mm i.d.) (Nacalai Tesque, Inc.), hexane/EtOAc (5:1), 8.0 mL/min, 35 °C; system II: *Shimpack PREP-ODS* (25 cm × 20 mm i.d.) (Shimadzu corp., Kyoto, Japan), MeOH, 8.0 mL/min, 35 °C; system III: *Cosmosil 5C~18~-MS-II column* (25 cm × 20 mm i.d.) (Nacalai Tesque, Inc.), MeOH/H~2~O (95:5), flow rate, 4.0 mL/min, 35 °C; system IV: *Cosmosil 5C~18~-MS-II column*, MeOH/H~2~O (9:1), 4.0 mL/min, 35 °C.

3.2. Materials {#sec3dot2-ijms-18-02479}
--------------

The fruiting bodies of *P. eryngii* were purchased from HOKUTO Corp. They were cultivated in Kagawa, Japan (Sample 1 in 2011, and Sample 2 in 2014). A voucher material has been deposited in the Herbarium of the Laboratory of Medicinal Chemistry, Osaka University of Pharmaceutical Sciences.

3.3. Extraction and Isolation {#sec3dot3-ijms-18-02479}
-----------------------------

### 3.3.1. Sample 1 {#sec3dot3dot1-ijms-18-02479}

Sample 1 (fruiting bodies of *P. eryngii* (21 kg, fresh weight)) was extracted with MeOH under reflux (1 week, 4 times). The MeOH extract (170 g) was then divided into EtOAc and H~2~O fractions by liquid-liquid partition. The EtOAc fraction (60 g) was separated into 20 fractions (Fr. *S1*-A to *S1*-T) with SiO~2~ column chromatography (CC) (SiO~2~ (3.5 kg); CHCl~3~/EtOAc (1:0 to 0:1), and EtOAc/MeOH (5:1, and 0:1)).

Fr. *S1*-H (836.5 mg), CHCl~3~/EtOAc (10:1)-eluted fraction, was separated with SiO~2~ CC to yield 8 fractions, *S1*-H1 to *S1*-H8. Preparative HPLC (system I) of *S1*-H3 (185.7 mg), hexane/EtOAc (5:1)-eluted fraction, provided 7 fractions, *S1*-H3-1 to *SF*3-7. *S1*-H3-4 was identified as **4** (31.8 mg; retention time (*t*~R~) 19.2 min). Preparative HPLC (system II) of *S1-*H3-5 (5.4 mg, *t*~R~ 36.5 min) provided **3** (1.9 mg; *t*~R~ 37.5 min). Preparative HPLC (system IV) of *S1-*H6 (14.3 mg), hexane/EtOAc (3:1)-eluted fraction, provided **10** (1.3 mg, *t*~R~ 95.4 min) and **9** (1.7 mg, *t*~R~ 120.2 min).

Fr. *S1-*I (1072.3 mg), CHCl~3~/EtOAc (10:1)-eluted fraction, was separated with SiO~2~ CC to give 8 fractions, *S1*-I1 to *S1*-I10. Preparative HPLC (system I) of *S1*-I5 (45.2 mg), hexane/EtOAc (5:1)-eluted fraction, provided **5** (2.8 mg, *t*~R~ 42.7 min).

### 3.3.2. Sample 2 {#sec3dot3dot2-ijms-18-02479}

Sample 2 (fruiting bodies of *P. eryngii* (120 kg, fresh weight)) was extracted with MeOH under reflux (3 days, 4 times). The MeOH extract (2625 g) was divided into EtOAc and H~2~O fractions by liquid-liquid partition. The EtOAc fraction (240 g) was separated into 37 fractions (Fr. *S2*-A to *S2*-Z, and *S2*-a to *S2*-k) with SiO~2~ column chromatography (CC) (SiO~2~ (2.8 kg); CHCl~3~/EtOAc (1:0 to 0:1), and MeOH).

Fr. *S2-*V (3964.9 mg), CHCl~3~/EtOAc (1:1)-eluted fraction, was separated by SiO~2~ CC to give 8 fractions, *S2-*V1 to *S2-*V21. Preparative HPLC (system III) of Fr. *S2-*V4 (110.9 mg), hexane/EtOAc (1:1)-eluted fraction, provided **8** (1.5 mg; *t*~R~ 36.9 min) and **6** (6.3 mg; *t*~R~ 49.5 min). Preparative HPLC (system IV) of Fr. *S2*-V6 (451.6 mg), hexane/EtOAc (1:1)-eluted fraction, provided **7** (1.1 mg; *t*~R~ 59.8 min). Preparative HPLC (system IV) of Fr. *S2*-V7 (270.5 mg), hexane/EtOAc (1:1)-eluted fraction, provided **2** (3.0 mg; *t*~R~ 76.8 min). Preparative HPLC (system III) of Fr. *S2*-V10 (270.5 mg), hexane/EtOAc (1:1)-eluted fraction, provided **1** (1.9 mg; *t*~R~ 36.3 min).

### 3.3.3. (22*E*)-5α,6α-Epoxyergosta-8,14,22-triene-3β,7β-diol (**1**) {#sec3dot3dot3-ijms-18-02479}

\[α\]^20^~D~ −23.6 (*c* = 0.13, EtOH); IR *ν*~max~^KBr^ cm^−1^: 3451, 2960, 1697, 1557, 1456; UV *λ*~max~^EtOH^ nm (log*ε*): 206.0 (3.75), 242.0 (3.62); EIMS *m*/*z*: 426 \[M\]^+^ (71), 315 (27), 300 (57), 172 (83), 69 (100); HREIMS *m*/*z*: 426.3127 \[M\]^+^ (calcd for 426.3134: C~28~H~42~O~3~); ^1^H NMR (400 MHz, C~6~D~6~) *δ*~H~ ppm: 0.80 (s, H-19), 0.91 (d, 6.8 Hz), 0.93 (d, 6.4 Hz), 1.01 (d, 6.8 Hz), 1.07 (d, 6.4 Hz), 1.12 (s, H-18), 3.11 (d, 2.4 Hz, H-6), 3.83 (tt, 11.6, 4.8 Hz, H-3), 4.74 (br s, H-7), 5.24 (dd, 15.6, 8.4 Hz, H-22), 5.32 (overlapped, H-23), 5.33 (br s, H-15).

### 3.3.4. 5α,6α-Epoxyergost-8(14)-ene-3β,7α-diol (**2**) {#sec3dot3dot4-ijms-18-02479}

\[α\]^20^~D~ −112.2 (*c* = 0.13, EtOH); IR *ν*~max~^KBr^ cm^−1^: 3387, 2959, 2936, 2871, 1466, 1377; EIMS *m*/*z*: 430 \[M\]^+^ (5), 412 (100), 394 (57), 379 (58), 267 (23), 213 (21); HREIMS *m*/*z*: 430.3450 \[M\]^+^ (calcd for 430.3447: C~28~H~46~O~3~).

3.4. Inhibitory Effects against Human Recombinant Aromatase {#sec3dot4-ijms-18-02479}
-----------------------------------------------------------

Inhibitory assay against human recombinant aromatase was performed as described previously \[[@B28-ijms-18-02479],[@B29-ijms-18-02479]\].

3.5. Statistics {#sec3dot5-ijms-18-02479}
---------------

Values are described as the mean ± standard error of the mean (S.E.M.). Statistical analysis was performed by one-way analysis of variance, followed by Dunnett's test. Probability (*p*) values less than 0.05 were regarded as significant.

4. Conclusions {#sec4-ijms-18-02479}
==============

In this study, we isolated two new sterols (**1** and **2**) and elucidated their structures. They have 5α,6α-epoxy-7-hydroxy ergostane structure. In aromatase inhibitory assay, compounds **4** and **6** possessed comparable inhibitory effects (IC~50~ **4**: 8.1 µM; **6**: 2.8 µM) against human recombinant aromatase to aminoglutethimide (IC~50~ 2.0 µM). These results suggested that compounds **4** and **6** have potential as anti-breast cancer agents.

We thank Katsuhiko Minoura and Mihoyo Fujitake (Osaka University of Pharmaceutical Sciences) for the NMR and MS measurements.

Supplementary materials can be found at [www.mdpi.com/1422-0067/18/11/2479/s1](www.mdpi.com/1422-0067/18/11/2479/s1).
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![Structure determination of compound **1**. (**A**) Key HMBC and ^1^H-^1^H COSY correlations of compound **1**; (**B**) Key NOE correlations of compound **1.** The atoms of C, H, and O were shown in grey, aqua, and red, respectively.](ijms-18-02479-g002){#ijms-18-02479-f002}

![Structure determination of compound **2**. (**A**) Key HMBC and ^1^H-^1^H COSY correlations of compound **2**; (**B**) Key NOE correlations of compound **2**. The atoms of C, H, and O were shown in grey, aqua, and red, respectively.](ijms-18-02479-g003){#ijms-18-02479-f003}

![Inhibitory effects of sterols (**1**--**10**) from *P. eryngii* against human recombinant aromatase. (**A**) Inhibitory effects of sterols (**4**, **6**) and aminoglutethimide at 1, 3, and 10 µM. (**B**) Inhibitory effects of sterols (**1--3**, **5**, **7**--**10**) at 10, 30, and 100 µM. Each value represents the mean ± the standard error (S.E.) of three determinations. Significant differences from the vehicle control (0 μM) group shown as \*\* *p* \< 0.01.](ijms-18-02479-g004){#ijms-18-02479-f004}
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###### 

^1^H and ^13^C NMR Data for Compounds **1** and **2** in CDCl~3~ (*δ* in ppm; *J* in Hz).

             1            2                                                                                                    
  ---------- ------------ --------------------------- ------------ ------------- -------- ---------------------------- ------- ---
  Position   ***δ*~H~**   ***δ*~C~**                  ***δ*~H~**   ***δ*~C~**                                                  
  1α         2.01         (1H, multiplet (m))         31.0         t             1.46     (1H, m)                      32.2    t
  1β         1.86         (1H, m)                                                1.67     (1H, m)                              
  2          1.68         (2H, m)                     30.9         t             α 1.96   (1H, m)                      31.1    t
                                                                                 β 1.56   (1H, m)                              
  3          3.96         (1H, tt, *J* = 11.5, 5.4)   68.4         d             3.92     (1H, tt, *J* = 11.4, 3.0)    68.7    d
  4α         1.50         (1H, m)                     39.0         t             1.42     (1H, m)                      39.6    t
  4β         2.21         (1H, m)                                                2.13     (1H, dd, *J* = 13.2, 11.4)           
  5                                                   63.3         s                                                   67.8    s
  6          3.24         (1H, d, *J* = 2.4)          59.5         d             3.15     (1H, d, *J* = 3.5)           61.3    d
  7          4.85         (1H, br s)                  63.8         d             4.43     (1H, dd, *J* = 9.6, 3.5)     65.1    d
  8                                                   122.2        s                                                   125.1   s
  9                                                   138.8        s             2.35     (1H, m)                      38.7    d
  10                                                  38.3         s                                                   35.8    s
  11         2.19         (2H, m)                     22.2         t             α 1.49   (1H, m)                      19.0    t
                                                                                 β 1.40   (1H, m)                              
  12α        1.47         (1H, m)                     35.4         t             1.16     (1H, m)                      36.7    t
  12β        1.99         (1H, m)                                                1.95     (1H, m)                              
  13                                                  44.6         s                                                   43.1    s
  14                                                  147.7        s                                                   152.7   s
  15         5.55         (1H, br s)                  118.7        d             α 2.65   (1H, m)                      25.0    t
                                                                                 β 2.30   (1H, m)                              
  16α        2.27         (1H, m)                                                1.89     (1H, m)                      26.6    t
  16β        2.08         (1H, m)                     36.8         t             1.41     (1H, m)                              
  17         1.55         (1H, m)                     56.4         d             1.21     (1H, m)                      56.6    d
  18         0.82         (3H, s)                     15.6         quartet (q)   0.85     (3H, s)                      17.9    q
  19         1.30         (3H, s)                     23.6         q             0.87     (3H, s)                      16.5    q
  20         2.24         (1H, m)                     38.8         d             1.46     (1H, m)                      34.9    d
  21         1.04         (3H, d, *J* = 6.5)          21.0         q             0.93     (3H, d, *J* = 6.8)           19.1    q
  22         5.20         (1H, dd, *J* = 15.2, 7.6)   135.1        d             A 1.03   (1H, m)                      33.4    t
                                                                                 B 1.44   (1H, m)                              
  23         5.28         (1H, dd, *J* = 15.2, 7.9)   132.4        d             A 0.95   (1H, m)                      30.4    t
                                                                                 B 1.37   (1H, m)                              
  24         1.88         (1H, m)                     42.8         d             1.21     (1H, m)                      39.1    d
  25         1.48         (1H, m)                     33.1         d             1.58     (1H, m)                      31.5    d
  26         0.85         (3H, d, *J* = 6.8)          19.9         q             0.85     (3H, d, *J* = 7.1)           20.5    q
  27         0.83         (3H, d, *J* = 6.8)          19.6         q             0.78     (3H, d, *J* = 7.0)           17.6    q
  28         0.93         (3H, d, *J* = 6.8)          17.6         q             0.77     (3H, d, *J* = 6.9)           15.4    q
